The Meharry Medical College, Vanderbilt-Ingram Cancer Center, Tennessee State University Cancer Partnership will host the 15th Annual Cancer Retreat, Saturday, April 2, 8:30 a.m. – 3 p.m. The retreat will be held on the Meharry Medical College campus, Harold D. West Basic Sciences Building, Room M001.

Thousands of colorectal patients, families and supporters will gather in Nashville April 1 and 2 for the annual One Million Strong event to raise awareness about colorectal cancer.

Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.

For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system.

A multicenter study led by Vanderbilt University Medical Center (VUMC) investigators found that pancreatic cancer patients who underwent surgery and received chemotherapy lived longer and had fewer cancer recurrences in other parts of the body than patients who also received chemoradiation therapy.

Combining therapies for melanoma that induce cell senescence and that activate the immune response may improve outcomes for patients.

Investigators at Vanderbilt University Medical Center have published research regarding an important feature of colorectal cancer (CRC) that could eventually lead to the development of non-invasive means of monitoring cancer progression. After lung cancer, CRC is the second-most lethal cancer in the United States.